COVID‐19 Hospitalization Outcomes Among Patients With Autoimmune Rheumatic Diseases in the United States

Abstract

ObjectivesTo investigate the outcomes of COVID‐19‐related hospitalizations among patients with autoimmune rheumatic diseases (ARDs) in the United States in 2020. The primary outcome was in‐hospital mortality, and secondary outcomes included intubation rate, length of hospital stay (LOS), and total hospital charges (THCs).MethodsData for the study were obtained from the National Inpatient Sample database and included patients who were hospitalized with a principal diagnosis of COVID‐19. Univariable and multivariable logistic regression analyses were conducted to calculate odds ratios for the outcomes, adjusting for age, sex, and comorbidities.ResultsOut of the 1,050,720 COVID‐19 admissions, 30,775 had an ARD diagnosis. The unadjusted analysis showed higher mortality (12.21%) and intubation (9.2%) rates in the ARD group compared with the non‐ARD group (mortality rate: 11.14%, P = 0.013; intubation rate: 8.5%, P = 0.048). However, this difference was not significant after adjusting for confounding factors. The mean LOS and THCs did not differ significantly between the two groups. Among all ARD subgroups, the vasculitis group had significantly higher intubation rate, LOS, and THC.ConclusionThe study suggests that ARD is not associated with an increased risk of mortality or worse outcomes among patients hospitalized with COVID‐19 after adjusting for confounding factors. However, the vasculitis group had poorer outcomes during COVID‐19 hospitalizations. Further studies are needed to evaluate the effect of ARD activity and immunosuppressants on outcomes. Additionally, more research is required to investigate the relationship between COVID‐19 and vasculitis.